chronic obstructive pulmonary disease
Conditions
Interventions
the virus infection group:blank
bacterial infection group:blank
virus and bacterial infection group:blank
the non-infected group:blank
Sponsors
The First Affiliated Hospital Of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Aged 40-80 years old, male or female; 2) A confirmed diagnosis of COPD with post bronchodilator forced expiratory volume in 1 s (FEV1) =80% of the predicted normal value and FEV1/forced vital capacity (FVC) =0.7, consistent with GOLD stage II–IV disease (GOLD 2018); 3) they are in an acute exacerbation period, hospitalized for acute exacerbations [1, 24] , when be recruited; 4) The patient did not take antiviral drugs within 1 week, and not take the antibiotic drugs within 1 month before enrollment; 5) Ability to communicate in language or text, agree to participate in the study and sign informed consent, and have the ability to complete the trial-related examination.
Exclusion criteria
Exclusion criteria: 1) Other serious diseases except the chronic obstructive pulmonary disease: severe liver dysfunction (ALT or AST = 3 times normal value); severe renal insufficiency (serum creatinine > 433umol/L); chronic congestive heart failure (Cardiac function NYHA III-IV), affecting the examination; 2) Clinical diagnosis of lung cancer, bronchiectasis, pneumoconiosis or other simple restrictive ventilatory dysfunction; 3) Active tuberculosis; 4) Pulmonary fungal disease; 5) Patients who underwent a pneumonectomy; 6) The systemic (oral or intravenous) hormone dose that requires long-term use is unstable (i.e., the dose stabilization time is less than 6 weeks) or the hormone dose exceeds the dose equivalent to prednisone 10 mg/d, or long-term use of antibiotics; 7) Patients with a history of asthma, allergic rhinitis, or a blood eosinophil count of =600/mm3 (0.6×10^9/L) within 4 weeks; 8) Immunodeficient patients, such as malignant tumors, organ or bone marrow transplants and AIDS or nearly 3 months of taking immunosuppressive organs or bone marrow transplant patients; 9) History of chronic alcohol abuse, drug abuse, or any factors that affect compliance; 10) Patients who are participating in any interventional clinical study 3 months ago; 11) Other reasons that the investigators consider unsuitable for participation in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| expectoration or induction of phlegm;pharyngeal swab;bronchoalveolar lavage fluid;respiratory mucosa biopsy tissue;Lung function;CAT and mMRC scores;serum; | — |
Countries
China
Contacts
Public ContactYang Zifeng
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed